CYBN Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 16.73%, SMA50 26.13%, SMA200 19.26%). The stock’s 14-day RSI is 69.15 (firm momentum), while the ATR of 0.47 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.83% below its high and over 72.14% above its low.

Cybin Inc. generated EPS of -$3.89 over the past year. Five-year average earnings growth is -232.48%. Wall Street analysts project EPS growth of 16.8% annually over the next five years. The latest quarter delivered EPS of -$1.39. The next quarter is forecast at -$0.58. Next year's EPS is expected at $22.98. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $150.00 to $35.00. The high target offers 1711.59% upside. The low target suggests 322.71% downside. The mean target is $68.00. This offers 721.26% upside. Cybin Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 87.84%. The prior quarter beat by 115.69%. Over the last six quarters, Apple has recorded several small beats. These include -50.0% in August 08, 2024.

Cybin Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.52. This means the shares are trading above this model’s fair value.

Cybin Inc. (AMEX:CYBN) closed at $8.28 USD, gaining $0.10 (1.22%) from the previous close of $8.18. The stock is currently mid-range between its 52-week high and low $4.81 and $10.72. With a market capitalization of about $413.02 million, Cybin Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.79). Key stats such as the average daily volume over the past year has been around 874.38 thousand shares, in line with its 52-week average. Headquartered in Toronto, ON, Cybin Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Eric So, the company employs approximately 50 people and listed since September 13, 2019. Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics.

Our AI price prediction model suggests that Cybin Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 20.05%, with price expected at $9.94 by January 16, 2026, within a range of $9.62 to $10.24 3-Month Outlook: Projected fall of -6.04%, reaching $7.78 by April 02, 2026, with a range of $7.33 to $8.16. 1-Year Outlook: Projected gain of 13.65%, with price at $9.41 by January 01, 2027, within a range of $0.00 to $12.82.

Cybin Inc. (AMEX:CYBN) shares are flat 1.22% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cybin Inc. trading at a premium to the broader market with a P/E of -2.76. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $48.78, suggesting 489.13% upside. Our AI forecast model points to short-term strength (20.05% over two weeks), a medium-term fall (-6.04% over three months), and a longer-term gain (13.65% over one year), with expected trading ranges indicating moderate volatility.

Cybin Inc. trades at a P/E ratio of -2.76, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.97 suggesting the stock is closer to book value. The P/FCF stands at -4.94, also below market averages.